OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial
Penella J. Woll, Piers Gaunt, Sarah Danson, et al.
Lung Cancer (2022) Vol. 171, pp. 26-33
Open Access | Times Cited: 33
Penella J. Woll, Piers Gaunt, Sarah Danson, et al.
Lung Cancer (2022) Vol. 171, pp. 26-33
Open Access | Times Cited: 33
Showing 1-25 of 33 citing articles:
SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection
Qian Wang, Zeynep H. Gümüş, Cristina Colarossi, et al.
Journal of Thoracic Oncology (2022) Vol. 18, Iss. 1, pp. 31-46
Open Access | Times Cited: 110
Qian Wang, Zeynep H. Gümüş, Cristina Colarossi, et al.
Journal of Thoracic Oncology (2022) Vol. 18, Iss. 1, pp. 31-46
Open Access | Times Cited: 110
Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study
Matthew Krebs, Jean‐Pierre Delord, T.R. Jeffry Evans, et al.
Lung Cancer (2023) Vol. 180, pp. 107216-107216
Open Access | Times Cited: 23
Matthew Krebs, Jean‐Pierre Delord, T.R. Jeffry Evans, et al.
Lung Cancer (2023) Vol. 180, pp. 107216-107216
Open Access | Times Cited: 23
P53 and Rb Aberrations in Small Cell Lung Cancer (SCLC): From Molecular Mechanisms to Therapeutic Modulation
Kostas A. Papavassiliou, Amalia A. Sofianidi, Vassiliki A. Gogou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2479-2479
Open Access | Times Cited: 11
Kostas A. Papavassiliou, Amalia A. Sofianidi, Vassiliki A. Gogou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2479-2479
Open Access | Times Cited: 11
Recent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics
Subhadeep Das, Shayak Samaddar
Cancers (2025) Vol. 17, Iss. 2, pp. 255-255
Open Access | Times Cited: 1
Subhadeep Das, Shayak Samaddar
Cancers (2025) Vol. 17, Iss. 2, pp. 255-255
Open Access | Times Cited: 1
Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy
Yunfei Chen, Hui Li, Yun Fan
Cancer Treatment Reviews (2023) Vol. 120, pp. 102606-102606
Open Access | Times Cited: 16
Yunfei Chen, Hui Li, Yun Fan
Cancer Treatment Reviews (2023) Vol. 120, pp. 102606-102606
Open Access | Times Cited: 16
Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929
Nagla Abdel Karim, Jieling Miao, Karen L. Reckamp, et al.
Journal of Thoracic Oncology (2024)
Closed Access | Times Cited: 7
Nagla Abdel Karim, Jieling Miao, Karen L. Reckamp, et al.
Journal of Thoracic Oncology (2024)
Closed Access | Times Cited: 7
Extensive-Stage Small-Cell Lung Cancer: Current Landscape and Future Prospects
Yu Saida, Satoshi Watanabe, Toshiaki Kikuchi
OncoTargets and Therapy (2023) Vol. Volume 16, pp. 657-671
Open Access | Times Cited: 14
Yu Saida, Satoshi Watanabe, Toshiaki Kikuchi
OncoTargets and Therapy (2023) Vol. Volume 16, pp. 657-671
Open Access | Times Cited: 14
Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification
Enrico Caliman, Sara Fancelli, Giulia Petroni, et al.
Lung Cancer (2022) Vol. 175, pp. 88-100
Open Access | Times Cited: 21
Enrico Caliman, Sara Fancelli, Giulia Petroni, et al.
Lung Cancer (2022) Vol. 175, pp. 88-100
Open Access | Times Cited: 21
Novel Therapeutic Options for Small Cell Lung Cancer
Stefania Canova, B. Trevisan, Maria Ida Abbate, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 11, pp. 1277-1294
Open Access | Times Cited: 12
Stefania Canova, B. Trevisan, Maria Ida Abbate, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 11, pp. 1277-1294
Open Access | Times Cited: 12
PARP Inhibitors as Therapy for Small Cell Lung Carcinoma: A Systematic Review and Meta-Analysis of Clinical Trials
Samuel Pratama, Lowilius Wiyono, Martien Silviandy Setiawan, et al.
Cancer Treatment and Research Communications (2025), pp. 100874-100874
Open Access
Samuel Pratama, Lowilius Wiyono, Martien Silviandy Setiawan, et al.
Cancer Treatment and Research Communications (2025), pp. 100874-100874
Open Access
Unveiling Novel Targets in Lung Tumors for Enhanced Radiotherapy Efficacy: A Comprehensive Review
Faris Anad Muhammad, Ayat Hussein Adhab, Morug Salih Mahdi, et al.
Journal of Biochemical and Molecular Toxicology (2025) Vol. 39, Iss. 3
Closed Access
Faris Anad Muhammad, Ayat Hussein Adhab, Morug Salih Mahdi, et al.
Journal of Biochemical and Molecular Toxicology (2025) Vol. 39, Iss. 3
Closed Access
Unmet needs in maintenance therapy for extensive stage small cell lung cancer
Luís Paz-Ares, B. K. Gupta, Javier Baena, et al.
Clinical Lung Cancer (2025)
Closed Access
Luís Paz-Ares, B. K. Gupta, Javier Baena, et al.
Clinical Lung Cancer (2025)
Closed Access
Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Cancer: Systematic Review and Network Meta-Analysis
Geqiong Xiao, Junwei Yan, Zhidong Cai, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Geqiong Xiao, Junwei Yan, Zhidong Cai, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Olaparib monotherapy or combination therapy in lung cancer: an updated systematic review and meta- analysis
Sajjad Hajihosseini, Elham Emami, Seyed Rasoul Zakavi, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Sajjad Hajihosseini, Elham Emami, Seyed Rasoul Zakavi, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Replication stress response and radioresistance in lung cancer: Mechanistic insights and advanced therapeutic approaches
Moumita Kundu, Ankita Dey, Sanjukta Dasgupta
Current Problems in Cancer (2025) Vol. 56, pp. 101206-101206
Closed Access
Moumita Kundu, Ankita Dey, Sanjukta Dasgupta
Current Problems in Cancer (2025) Vol. 56, pp. 101206-101206
Closed Access
Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis
Meng‐Fei Dai, Xin Wang, Wenxiu Xin, et al.
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 7, pp. 613-622
Closed Access | Times Cited: 3
Meng‐Fei Dai, Xin Wang, Wenxiu Xin, et al.
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 7, pp. 613-622
Closed Access | Times Cited: 3
Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer
Sehhoon Park, Yu Jung Kim, Young Joo Min, et al.
Cancer (2023) Vol. 130, Iss. 4, pp. 541-552
Open Access | Times Cited: 7
Sehhoon Park, Yu Jung Kim, Young Joo Min, et al.
Cancer (2023) Vol. 130, Iss. 4, pp. 541-552
Open Access | Times Cited: 7
Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial
Jiuang Mao, Jianjiao Ni, Li Chu, et al.
Radiation Oncology (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 2
Jiuang Mao, Jianjiao Ni, Li Chu, et al.
Radiation Oncology (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 2
Challenges and future perspectives for the use of temozolomide in the treatment of SCLC
Elisa Andrini, Gianluca Ricco, Arianna Zappi, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102798-102798
Closed Access | Times Cited: 2
Elisa Andrini, Gianluca Ricco, Arianna Zappi, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102798-102798
Closed Access | Times Cited: 2
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities
Jing Zhang, Xiaoping Zeng, Qiji Guo, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Jing Zhang, Xiaoping Zeng, Qiji Guo, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Olaparib-associated toxicity in cancer patients: a systematic review and meta-analysis
Wenfang Jin, Qing Yang, Zhifeng Zhang, et al.
European Journal of Clinical Pharmacology (2024)
Closed Access | Times Cited: 2
Wenfang Jin, Qing Yang, Zhifeng Zhang, et al.
European Journal of Clinical Pharmacology (2024)
Closed Access | Times Cited: 2
Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis
Xiu Chen, Qinglian Wen, Liqiu Kou, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Xiu Chen, Qinglian Wen, Liqiu Kou, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions
Chenyue Zhang, Chenxing Zhang, Kai Wang, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 5
Chenyue Zhang, Chenxing Zhang, Kai Wang, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 5
Accurate treatment of small cell lung cancer: Current progress, new challenges and expectations
Chenyue Zhang, Haiyong Wang
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 5, pp. 188798-188798
Closed Access | Times Cited: 8
Chenyue Zhang, Haiyong Wang
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 5, pp. 188798-188798
Closed Access | Times Cited: 8
Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: A systematic review and Bayesian network analysis
Hekai Shi, Nuojin Guo, Zeming Zhao, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
Hekai Shi, Nuojin Guo, Zeming Zhao, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
